(NYSE:TMO) WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofiās state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companiesā strategic partnership to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. The Ridgefield facility is now part of Thermo Fisher's pharma services business withi
Related Questions
How will the acquisition affect Thermo Fisher Scientificās revenue forecasts and earnings guidance?
What synergies and capacity expansions are expected from the Ridgefield site integration, and how might they impact the competitive landscape?
Will the dealās undisclosed terms and potential financing structure create any nearāterm volatility or valuation pressure on the stock?